ABSTRACT

Background

An estimated 20%–40% of cancer patients will develop brain metastases. Whole-brain radiotherapy (WBRT) is the standard treatment for patients with brain metastases. Although WBRT can reduce neurologic symptoms, the median survival following WBRT is between 3 and 6 months. Given this limited survival, it is important to consider quality of life (QOL) when treating patients with brain metastases. However, few studies have focused on QOL and improvement in patient-rated symptoms as primary outcomes.

Objective

For an accurate measurement of the extent to which previous trials have utilized QOL tools to evaluate the efficacy of WBRT for treatment of brain metastases, we undertook a literature review to examine the common endpoints and QOL instruments used.

Methods

We conducted a systematic search using the MEDLINE (1950 to December 2007) and Cochrane Central Register of Controlled Trials (4th quarter 2007) databases. Eligible studies investigated WBRT in one of the study arms. The following outcomes were included: median survival, overall survival, neurologic function, 1-year local control, and overall response; use of QOL instruments, performance status scales, and neurologic function assessments; and use of other assessment tools. Patient-rated QOL instruments were defined as those that strove to assess all dimensions of QOL; observer-rated performance instruments such as the Karnofsky performance status (KPS) were deemed to be performance scales.

Results

We identified sixty-one trials that included WBRT as a treatment for brain metastases. Of these sixty-one trials, nine evaluated the treatment of a single brain metastasis, and fifty-two evaluated the treatment of multiple brain metastases. Although fifty-five of the trials employed a QOL instrument, few trials focused on QOL as an outcome. We found 23 different instruments used to evaluate QOL. The most commonly employed instrument was the KPS (n = 33), followed by various neurologic function classification scales (n = 21). A preponderance of the studies used 1 (n = 26, 43%) or 2 (n = 21, 34%) QOL instruments.

A total of fourteen published trials on brain metastases included an evaluation of the study population’s QOL. Those trials included three that used the Functional Assessment of Cancer Therapy–General scale and Brain subscale instrument, three that used the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (C30) and the Brain Cancer Module 20 instrument, two that used study-designed QOL instruments, one that used the Edmonton Symptom Assessment Scale, two that used the Spitzer Quality of Life index, and three that used the KPS to evaluate QOL. Some trials reported deterioration in QOL after WBRT in patients with poorer prognosis; other trials detected an improvement in QOL after WBRT in patients with better prognosis.

Conclusions

To date, fourteen trials in brain metastases that have included an evaluation of the study population’s QOL have been published. Although some studies showed that certain parameters of QOL deteriorate after WBRT, other studies showed that QOL in patients with better prognosis is improved after WBRT. Because a standard, validated QOL instrument has not been used for this patient population, a comparison of findings concerning QOL between the studies is difficult. The present review emphasizes the need to include QOL measures in future WBRT clinical trials for brain metastases.

KEY WORDS

Brain metastasis, quality of life, whole-brain radiotherapy
1. INTRODUCTION

Brain metastases are a cause of significant morbidity. An estimated 20%–40% of cancer patients will develop brain metastases during their illness. The most common primary cancers that metastasize to the brain are lung, breast, and gastrointestinal cancers. Depending on the location of the brain metastases, patients may suffer from neurologic symptoms that include headaches, focal weakness, mental disturbances, behavioral changes, seizures, speech difficulty, and ataxia. The prognosis for patients with brain metastases is generally poor; median survival is 1 month for patients not receiving treatment. Use of corticosteroids to reduce cerebral edema has been associated with symptom improvement.

Whole-brain radiotherapy (WBRT) is the standard treatment for brain metastases. About 30%–40% of affected patients present with a single brain metastasis, but most present with multiple lesions. The objective of WBRT is to provide symptomatic relief, to allow for tapering of the dose of corticosteroids, and to possibly improve survival. Although many trials have shown that WBRT can reduce neurologic symptoms, median survival following a diagnosis of brain metastases is generally only 3–6 months. Patients with a solitary brain metastasis, good performance status, and controlled extracranial disease may be considered for more aggressive treatment such as surgery with postoperative radiotherapy or stereotactic radiosurgery. Radiosensitizers, chemotherapy, and various radiotherapy dose fractionation schedules have also been explored to improve the outcome of brain metastases.

The World Health Organization (WHO) describes health as a “state of complete physical, mental, and social well-being and not merely the absence of disease or infirmity.” This subjective, multidimensional definition of health encourages health care professionals to focus not only on a patient’s length of life, but also his or her quality of life (QOL). Quality of life can be seen as a balance between minimizing treatment risks and maximizing benefits, including physical and psychological effects. Because patients with brain metastases have limited survival, treatment options that are less morbid and that maximize QOL are essential.

An Outcomes Working Group was formed by the Health Services Research Committee in the American Society of Clinical Oncology to define the outcomes of cancer treatment that should be considered for assessment and cancer treatment guidelines. Quality of life was rated as an endpoint secondary in importance only to survival. The group suggested that these two patient outcomes—survival and QOL—should take precedence over cancer outcomes such as response rate. The importance of including QOL as a component of treatment assessment was also emphasized by Tannock, who wrote, “When cure is elusive, it is time to start treating the patient and not the tumor.”

Previous clinical trials have defined the efficacy of treatment using some of the following endpoints: survival, response, radiologic or imaging response, observer-rated neurologic symptoms, time to recurrence of intracranial disease, cause of death, and preservation of the ability to function independently. However, few studies have focused on QOL and improvement in patient-rated symptoms as primary outcomes.

To accurately measure the extent to which previous trials utilized QOL tools to evaluate the efficacy of radiotherapy for treatment of brain metastases, we undertook a literature review to examine the common endpoints and QOL instruments used.

A preponderance of the published trials used a performance status scale such as the Karnofsky performance status (KPS) to quantify the general well-being of patients with brain metastases. The purpose of a performance status assessment is to quantify a patient’s level of function, level of ambulation, and ability for self-care. The KPS is rated in increments of 10 on a scale of 0 to 100, with 100 meaning “normal, no complaints, no signs of disease” and 0 meaning “death”. A score is assigned based on assessment by an observer such as a physician, nurse, or researcher. Trials often use a performance score to describe their study population or as a component of the study’s exclusion criteria—for example, patients below a certain KPS score are deemed ineligible.

Although performance status is one of the dimensions of QOL, QOL is subjective and should reflect how a patient feels. The KPS was evaluated previously, and although it was found to be a reliable instrument, it did not capture the overall concept of QOL. In the present study, only patient-rated instruments that strive to assess all dimensions of QOL were deemed to be QOL instruments; observer-rated performance instruments such as the KPS were deemed to be performance scales.

2. METHODS

2.1 Search Strategy

We conducted a systematic search of the MEDLINE (1950 to December 2007) and Cochrane Central Register of Controlled Trials (4th quarter 2007) databases. The terms “brain neoplasms” and “brain metastases” were used. The subheading “secondary” was selected to narrow the search to metastases to the brain (so as to exclude primary brain cancer). That search was combined with the terms “radiotherapy” or “quality of life.” Relevant articles and abstracts were reviewed, and the reference lists from these sources were manually searched for additional relevant trials. The search was not limited by year of publication.

2.2 Inclusion Criteria

Articles were included in the literature review if they met these criteria:

- **Population** Studies of adult participants who had been diagnosed with one or more brain metastases.
metastases by computed tomography or magnetic resonance imaging.

- **Intervention** WBRT in one study arm.
- **Type of study** Randomized or quasi-randomized trials and prospective or retrospective cohort studies.
- **Outcomes** Survival, QOL, symptom control, neurologic function, toxicity, response of brain metastases to treatment, cause of death, duration of functional independence, and intracranial progression-free duration.

### 2.2 Exclusion Criteria

Articles were excluded from the literature review if they were

- individual case reports or review articles,
- published in languages other than English, or
- phase I and II trials for which phase III trials were already available.

### 2.3 Data Extraction

The following information extracted from the studies:

- Number of patients accrued and evaluated in each study arm
- Patient inclusion and exclusion criteria for studies that included chemotherapy, surgery, or radiosurgery in one study arm
- Treatment details such as chemotherapy drugs or radiosensitizer
- Total dose and fractionation schedule for WBRT trials
- Outcomes such as median survival, overall survival, neurologic function, 1-year local control, and overall response
- Use of QOL instruments, performance status scales, and neurologic function assessments
- Other assessment tools, if used

### 3. RESULTS

We identified sixty-one trials that treated patients using WBRT in at least one study arm.

#### 3.1 Single Brain Metastasis

Nine of the sixty-one studies evaluated treatment of patients with a solitary brain metastasis. Two published trials and one abstract examined the role of surgery and WBRT as compared with WBRT alone.

One trial assessed the effectiveness of surgery and WBRT as compared with surgery alone. Epstein et al. compared survival outcomes of various dose escalation schedules. One multi-institutional retrospective study investigated the use of radiosurgery and WBRT. A study by Jyothirmayi et al. examined the efficacy of radiosurgery at diagnosis, radiosurgery and WBRT at diagnosis, and radiosurgery at recurrence. Another study compared the outcomes of radiosurgery alone, WBRT alone, and radiosurgery with WBRT. Roos et al. investigated the results of randomizing patients to WBRT or observation after the patients had been treated with surgery or radiosurgery. Their study also examined the QOL of the study population.

#### 3.2 Multiple Brain Metastases

We identified fifty-two studies involving treatment of multiple brain metastases. One trial examined the use of corticosteroids and WBRT as compared with WBRT alone. In another trial, all patients received dexamethasone before WBRT, after which they were randomized to WBRT with a dose of dexamethasone or to WBRT alone. Two retrospective trials examined the outcomes of multiple treatments including WBRT, surgery, chemotherapy, or supportive care. Twelve studies examined the use of various WBRT dose fractionation schedules, and seven trials assessed the efficacy of radiosensitizers and WBRT as compared with WBRT alone. Chemotherapy and WBRT were compared in eight studies. Five trials examined the efficacy of whole-brain re-irradiation in patients with brain metastases. One study randomized patients with 1–3 brain metastases to WBRT or WBRT followed by stereotactic radiosurgery boost. One retrospective study examined the outcomes of WBRT or Gamma Knife radiosurgery. One randomized trial examined the combination of WBRT and radiosurgery as compared with WBRT alone for patients with 2–4 brain metastases. Three other studies looked at WBRT and radiosurgery as compared with radiosurgery alone for patients with 1–3 brain metastases, 1–4 brain metastases, and single or multiple brain metastases. One study focused on QOL and the patients’ perspectives regarding management-related complications in addition to the radiosurgery. Another study investigated the survival and QOL of patients who were randomized to WBRT with efaproxiral or to WBRT alone. Six other studies examined the role of QOL or patient-rated symptoms when assessing the effectiveness of WBRT. Two studies assessed the neurocognitive function (NCF) of patients who had been treated with WBRT and a radiosensitizer or with WBRT alone. Lastly, one study investigated both NCF and QOL of patients treated with WBRT.

#### 3.3 Study Outcomes

Tables I–IX present the outcomes of the trials outlined in the previous subsection. The endpoints of overall median survival, overall survival at 6 months, 1-year local control, overall response rate, QOL, neurologic function, and symptom control are reported when available. The number of QOL instruments used in each study is also recorded.
### TABLE I: Studies involving patients with a single brain metastasis

| Reference                  | Study arms                                                                 | Patients (n) | Median Survival (months) | Overall Survival at 6 mo. (% of n) | QOL assessment | Neurologic function or symptom control | Other assessment | Tools instruments (n) |
|----------------------------|----------------------------------------------------------------------------|--------------|--------------------------|-----------------------------------|----------------|---------------------------------------|------------------|-----------------------|
| Auchter et al., 1996       | Radiosurgery + WBRT (range: 25–40 Gy)                                       | 122 a        | 14                       | (53)                              | KPS            | Duration of functional independence  | Cause of death   | 1                     |
| Epstein et al., 1993       | 32 Gy in 20 fractions BID + boost:                                           | 30           | 4.9                      | 53                                | KPS            | Neurologic function classification   |                  | 2                     |
| Jyothirmayi et al., 2001   | Radiosurgery (at diagnosis)                                                 | 45           | 10                       | KPS                              |                | Overall response rate               | Toxicity         | 1                     |
| Li et al., 2000            | 35–45 Gy/18–25 fractions                                                    | 29           | 5.7                      | KPS                              |                | Intracranial progression-free duration |                  | 1                     |
| Mintz et al., 1996         | Radiosurgery                                                               | 23           | 9.3                      | (p<0.0001)                        |                | Cause of death                       |                  | 2                     |
| Noordijk et al., 1994      | Radiosurgery + 30–45 Gy/15–25 fractions                                     | 18           | 10.6                     | (p=NS)                           |                | Cause of death                       |                  | 3                     |
| Patchell et al., 1990      | 36 Gy/12 fractions + surgery                                                | 25           | 9.2                      | 17 (68)                          | KPS            | Duration of functional independence  | Cause of death   | 1                     |
| Patchell et al., 1998      | Surgery + 54 Gy/28 fractions                                                 | 49           | 48 weeks                 | 5 (22)                           | KPS            | Cause of death                       |                  | 1                     |
| Roos et al., 2006          | 36 Gy/18 fractions                                                         | 46           | 43 weeks                 |                                   |                | MMSE                                  |                  | 3                     |

a 5 Patients declined WBRT, but were included in the study.
b 76% of the study population received 20 Gy/2 fr.
c abstract only.

qol = quality of life; WBRT = whole-brain radiation therapy; KPS = Karnofsky performance status; BID = twice daily; ECOG = Eastern Cooperative Oncology Group; NS = nonsignificant; FIS = Functionally Independent Survival; EORTC QLQ-C30 = European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire; EORTC BCM 20 = European Organization for Research and Treatment of Cancer Brain Cancer Module.
| Reference        | Study arms                                      | Patients (n) | Survival      | Tools | Neurologic assessment or symptom control | QOL instruments (n) |
|------------------|------------------------------------------------|--------------|--------------|-------|------------------------------------------|--------------------|
| Bach et al., 1996 | 50.4 Gy/28 fractions, 5 fractions/week, 22 Gy/4 fractions | 44           | 160 days (74–2021 days)³ | ECOG  |                                          | 1                  |
|                   | SCLC patients post-chemotherapy (p<0.00001)     | 57           | 88 days      |       |                                          |                    |
|                   |                                                 |              | (20–948 days), |       |                                          |                    |
| Borgelt et al., 1980 | 30 Gy/10 fractions, 30 Gy/15 fractions, 40 Gy/15 fractions | 233          | 4.2 months   | GPS   | Neurologic function classification        | 2                  |
|                   | Study 1: 30 Gy/10 fractions                     | 217          | (3.7–4.6 months) | Neurologic | classification                          |                    |
|                   | Study 2: 20 Gy/5 fractions                     | 447          | 3.5 months   |       |                                          |                    |
|                   | Study 1: 10 Gy/1 fractions                     | 26           | 3.5 months   | GPS   | Neurologic function classification        | 2                  |
|                   | Study 2: 12 Gy/2 fractions                     | 33           | 3.0 months   |       | Neurologic function classification        |                    |
|                   | Study 2: 20 Gy/5 fractions                     | 31           | 2.8 months   |       | Neurologic function classification        |                    |
| Chatani et al., 1994 | Normal lactate dehydrogenase (LDH):       | 46           | 5.4 months   |       |                                          | 0                  |
|                   | (abstract) 30 Gy/10 fractions                  | 46           | 4.8 months   |       |                                          |                    |
|                   | High LDH 30 Gy/10 fractions                    | 35           | 3.4 months   |       |                                          |                    |
|                   | 50 Gy/20 fractions                             | 35           | 2.4 months   |       |                                          |                    |
|                   |                                                  |              | (p<0.001)    |       |                                          |                    |
|                   |                                                  |              | (p=0.943)    |       |                                          |                    |
| Gelber et al., 1981 | 20 Gy/5 fractions, 30 Gy/10 fractions, 40 Gy/15 fractions | 46           | Breast patients: 160 |     | gase Neologic function classification    | 2                  |
|                   | Study 1: 20 Gy/5 fractions                     | 33           | 3.0 months   |       | gase Neologic function classification    |                    |
|                   | Study 2: 30 Gy/10 fractions                    | 31           | 2.8 months   |       | gase Neologic function classification    |                    |
| Haie–Meder et al., 1993 | 18 Gy/3 fractions/3 days, 2 courses:         | 110          | 4.2 months   |       |                                          | 1                  |
|                   | 18 Gy/3 fractions/3 days followed 1 month later by another 18 Gy/3 fractions/3 days, or 18 Gy/3 fractions/3 days followed 1 month later by another 25 Gy/10 fractions/14 days | 106          | 5.3 months   |       |                                          |                    |
### TABLE II (continued)

| Reference            | Study arms                        | Patients (n) | Survival Median (range) | Overall at 6 mo. (n (%) | Tools QOL assessment | Neurologic function or symptom control | QOL instruments (n) |
|----------------------|-----------------------------------|--------------|-------------------------|-------------------------|----------------------|----------------------------------------|---------------------|
| Harwood et al., 1977 | 10 Gy/1 fractions                 | 51           | 4.4 months (p=0.082)    | 14 (27)                 | Functional status    | Neurologic function classification     | 2                   |
|                      | 30 Gy/10 fractions                | 50           | 4.0 months              | 20 (40)                 |                      |                                        |                     |
| Kurtz et al., 1981   | 30 Gy/10 fractions                | 130          | 18 weeks (p=NS)         |                         | Performance status   | Neurologic function classification     | 2                   |
|                      | 50 Gy/20 fractions                | 125          | 17 weeks                |                         |                      |                                        |                     |
| Murray et al., 1981  | 54.4 Gy/34 fractions BID (over 17 days) | 216         | 4.5 months (p=0.52)    | 84 (39)                 | KPS                  | Neurologic function classification     | 2                   |
|                      | 30 Gy/10 fractions (over 10 days) | 213          | 4.5 months              | 88 (41)                 |                      |                                        |                     |
| Nieder et al., 1997  | 30 Gy/10 fractions BID + surgery  | 11           | 3.3 months              |                         | KPS                  |                                        | 1                   |
|                      | 30 Gy/12 fractions BID            | 36           | 2.0 months              |                         |                      |                                        |                     |
|                      | 50.4 Gy/28 fractions BID          | 15           | 2.0 months              |                         |                      |                                        |                     |
|                      | 30 Gy/10 fractions (historical group) | 246         | 2.5 months              |                         |                      |                                        |                     |
|                      | 30 Gy/10 fractions + surgery (historical group) | 37         | 7.3 months              |                         |                      |                                        |                     |
| Portaluri et al., 2004 | 50 Gy/25 fractions              | 26           | 4 months (mean survival) | 6 (21)                  | Neurologic function classification | 1                   |
|                      | 30 Gy/10 fractions                | 48           | 5 months                | 18 (36)                 |                      |                                        |                     |
|                      | 20 Gy/5 fractions                 | 42           | 5 months                | 9 (21)                  |                      |                                        |                     |
|                      | 9 Unusual fractionation treatments |             |                         |                         |                      |                                        |                     |
| Priestman et al., 1996 | 30 Gy/10 fractions              | 263          | 2.8 months (p=0.04)    | 46 (17)                 | ECOG                 | Neurologic function classification     | 2                   |
|                      | 12 Gy/2 fractions                 | 270          | 2.5 months              | 66 (25)                 |                      |                                        |                     |

---

**Notes:**

- Measured from the diagnosis of brain metastases.
- Exact dose and fractionation schedule not described.
- QOL = quality of life; SCLC = small-cell lung cancer; ECOG = Eastern Cooperative Oncology Group assessment; GPS = General Performance Status; KPS = Karnofsky performance status; NS = nonsignificant; BID = twice daily.
| Reference          | Study arms                                      | Patients (n) | Median survival | Overall response rate (CR+PR %) | QOL assessment | Tools Neurologic function or symptom control | Other assessment | QOL assessment |
|-------------------|------------------------------------------------|--------------|-----------------|---------------------------------|---------------|-----------------------------------------------|----------------|----------------|
| DeAngelis et al., 1989<sup>9</sup> | 30 Gy/10 fractions + lonidamine, 30 Gy/10 fractions | 19           | 4.0 months      | 37% (11.5 patients)             | KPS           | Cause of death                               | Toxicity        | 1              |
| Eyre et al., 1984<sup>24</sup>   | 30 Gy/10 fractions + metronidazole, 30 Gy/10 fractions | 57           | 2.8 months      | 27% (15 patients)               | KPS           | Neurologic function                          | Toxicity        | 1              |
| Johnson et al., 1998<sup>52</sup> | WBRT + pentoxifylline                          | 14           | 33 days         | 14% (2 patients)                | ECOG          | Neurologic function                          | Toxicity        | 2              |
| Kocher et al., 2005<sup>53</sup> | 36 Gy/12 fractions + topotecan                 | 47           | 5.1 months      | 58% (15 patients)               | KPS           | Cause of death                               | Toxicity        | 1              |
| Phillips et al., 1995<sup>21</sup> | 37.5 Gy/15 fractions + bromodeoxyuridine       | 34           | 4.3 months      | 63% of 22 patients evaluable for response (14 patients) | KPS | Neurologic function classification |
| Rhomberg et al., 2005<sup>25</sup> | 30 Gy/30 fractions + boost series of 2 Gy/dose, median of 43 Gy + razoxane, 30 Gy/30 fractions + boost series of 2 Gy/dose, median dose of 35 Gy | 8            | 5 months        | 62% (5 patients)                | KPS | Score Index for Stereotactic Radiosurgery (SN) for Brain Metastasis | Toxicity        | 1              |
| Stea et al., 2006<sup>54</sup>  | 30 Gy/10 fractions + efaproxiral, 30 Gy/10 fractions | 265<sup>a</sup> | 2.2 months      | 74% (27.9 patients)            | KPS | ECOG | 50% (20 patients) <sup>b</sup> |

<sup>a</sup> 18 Patients had radiosurgery and 3 patients had surgical resection after randomization.
<sup>b</sup> 13 Patients had radiosurgery and 9 patients had surgical resection after randomization.
<sup>c</sup> Response rate determined 3 months after treatment.

CR = complete response; PR = partial response; QOL = quality of life; NS = nonsignificant; KPS = Karnofsky performance status; ECOG = Eastern Cooperative Oncology Group assessment.
## Table IV

Multiple brain metastases: studies assessing the efficacy of whole-brain radiotherapy (WBRT) and chemotherapy

| Reference          | Study criteria                        | Study arms               | Patients (n) | Median survival (cr+pr) | Overall response rate (cr+pr) | QOL assessment                | Tools Neurologic function or symptom control | Other assessment | QOL instruments (n) |
|--------------------|---------------------------------------|--------------------------|--------------|-------------------------|-------------------------------|-------------------------------|-----------------------------------------------|-----------------|-------------------|
| Addeo et al., 2007 | Metastatic cancer to the brain        | 30 Gy/10 fractions + temozolomide | 59           | 13 months               | 44%                           | KPS                           | FACT-G                                        | Toxicity        | 2                 |
| Antonadou et al., 2002 | Metastatic cancer to the brain          | 30 Gy/10 fractions + temozolomide | Total of 134 patients randomized | 8.3 months (p=0.179) | 53.4%                         | KPS                           | FACT-BR                                      |                | 1                 |
| Guerrieri et al., 2003 | Metastatic NSCLC to the brain        | 20 Gy/5 fractions + carboplatin + cis-platinum | 21           | 3.7 months              | 29%                           | ECOS                          | Neurologic function classification            | Toxicity        | 2                 |
| Hidalgo et al., 1987 | Metastatic cancer to the brain        | 50 Gy/25 fractions + cis-platinum | 13           | 4.4 months (p=0.64)          | 10%                           | KPS                           | Neurologic function classification            | Toxicity        | 1                 |
| Postmus et al., 2000 | Metastatic NSCLC to the brain        | 30 Gy/10 fractions + teniposide | 60           | 3.5 months (p=0.179) | 57%                           | KPS                           | Neurologic function classification            | Toxicity        | 2                 |
| Robinet et al., 2001 | Metastatic NSCLC to the brain        | Delayed 30 Gy/10 fractions + cisplatin and vinorelbine | 76           | 6.0 months              | 33%                           | KPS                           | Order classification                          | Toxicity        | 2                 |
| Ushio et al., 1991 | Metastatic lung cancer to the brain   | 40 Gy total (1.5–2 Gy per dose) | 31           | 27 weeks                 | 36%                           | KPS                           | Intracranial response rate                   |                | 0                 |
| Verger et al., 2004 | Metastatic cancer to the brain        | 30 Gy/10 fractions + temozolomide | 41           | 4.5 months (p=NS) | 32%                           | Barthel index                  | KLPS                                          | Toxicity        | 2                 |

**Note:**
- CR = complete response; PR = partial response; QOL = quality of life; FACT-G = Functional Assessment of Cancer Therapy—General scale; FACT-BR = Functional Assessment of Cancer Therapy—Brain subscale; KPS = Karnofsky performance status; NSCLC = non-small-cell lung cancer; ECOG = Eastern Cooperative Oncology Group assessment; SCLC = small-cell lung cancer; NS = nonsignificant.
| Reference          | Study criteria       | Study arms                  | Patients (n) | Median survival | 1-Year local control | qOL assessment | Tools Neurologic function or symptom control | Other assessment | qOL instruments (n) |
|--------------------|----------------------|-----------------------------|--------------|-----------------|----------------------|---------------|---------------------------------------------|------------------|---------------------|
| Andrews et al., 2004 18 | 1–3 Brain metastases | 37.5 Gy/15 fractions + radiosurgery | 164         | 6.5 months (p=0.1356) | 82% (p=0.01) | KPS            | Cause of death 1                           | KPS 1            |
| Jawahar et al., 2002 66 | Brain metastases     | 30 Gy/10 fractions          | 86          | 5 months (p=0.0016)  | 71%                  | KPS            | Cause of death 1                           | KPS 1            |
| Kondziolka et al., 1999 20 | 2–4 Brain metastases | 30 Gy/12 fractions + Gamma Knife radiosurgery | 48          | 12 months (p=0.0016)  | 92%                  | KPS            | Cause of death 1                           | KPS 0            |
| Pirzkall et al., 1998 67 | 1–3 Brain metastases | 30–50 Gy total, median dose of 15 Gy + radiosurgery | 14          | 7.5 months (p=0.0016)  | 92%                  | KPS            | Cause of death 1                           | KPS 1            |
| Sneed et al., 1999 69  | Brain metastases     | Radiosurgery                | 158 (entire study population) | 5.5 months (p=0.13) | 89% | KPS | Cause of death 1                           | KPS 1            |
|                     |                      | Radiosurgery + WBRT         | 43           | 11.1 months (p=0.80) | 69% | KPS | Cause of death 1                           | KPS 1            |
|                     |                      | Radiosurgery                | 62           | 11.3 months          | 28% | KPS |                                      |                  |

qOL = quality of life; KPS = Karnofsky performance status; NS = nonsignificant.
| Reference            | Study arms                                                                 | Population sample | Overall median survival following RI | QOL Assessment | Tools | Other assessment | Instruments (n) |
|----------------------|-----------------------------------------------------------------------------|-------------------|--------------------------------------|----------------|-------|------------------|-----------------|
| Abdel-Wahab et al., 1997 $^{65}$ | Initial course: range 50–55 Gy, 1.5 Gy/fractions BID Whole-brain RI: median 30 Gy | 15                | 3.2 months                           | KPS            |       | Response to treatment | 1              |
| Hazuka et al., 1988 $^{61}$ | Initial course: median 30 Gy Whole- or partial-brain RI: median 25 Gy, 3.0 Gy/fractions | 37 whole-brain RI 7 partial-brain RI | 8 weeks |       |       | Response to treatment | 0              |
| Kurup et al., 1980 $^{62}$ | Initial course: 18 Gy/3 fractions, 20 Gy/5 fractions, 30 Gy/10 fractions Whole-brain RI: Most patients received a single 5-Gy dose or 46 Gy/20 fractions (5 Gy/week) | 56                | 3.5 months                           |       |       | Response to treatment | 0              |
| Rosenman et al., 1982 $^{63}$ | Initial course: 30 Gy/10 fractions – Elective whole-brain RI 24 $^{p=NS}$ – Therapeutic whole-brain RI $^{a}$ 28 |      | Difference in survival: | KPS |       | Response to treatment | 1              |
| Shehata et al., 1974 $^{64}$ | 60% Whole-brain RI (single 10-Gy dose) | 50                | 150 days                             | Neurologic function classification |       |       | Response to treatment | 1              |

$^{a}$ Defined by authors, because patients were re-irradiated when brain metastases occurred.
$^{qol}$ quality of life; BID = twice daily; KPS = Karnofsky performance status; NS = nonsignificant.
### TABLE VII  Multiple brain metastases: studies focused on quality of life (QOL), neurologic function, and neurocognitive function (NCF)

| Reference            | Study arms                          | Patients (n) | Median survival | QOL assessment                  | Tools Neurologic function or symptom control | Other assessment                     | QOL instruments (n) |
|----------------------|-------------------------------------|--------------|-----------------|---------------------------------|---------------------------------------------|----------------------------------------|---------------------|
| Bezjak et al., 2002  | 20 Gy/5 fractions                   | 75           | 86 days         | ECOG                            | Neurologic symptom checklist modelled after  | Analgesic measurement               | 5                   |
|                      |                                     |              |                 | FACT-G                          | FACT-BR                                    |                                        |                     |
|                      |                                     |              |                 |                                 | Neurologic function classification          |                                        |                     |
| Chow et al., 2005    | 20 Gy/5 fractions (n=138)           | 170          | 8 weeks         | KPS                             |                                             |                                        | 2                   |
|                      | 30 Gy/10 fractions (n=7)            |              |                 |                                 |                                             |                                        |                     |
|                      | Other dose fractionations (n=25)    |              |                 |                                 |                                             |                                        |                     |
| Gerrard et al., 2003 | First study: 12 Gy/2 fractions      | 18           | 6 weeks         | KPS, EORTC QLQ-30, and BCM 20   | Neurologic function classification          | Time to progression                   | 4                   |
|                      | Second study: 20 Gy/5 fractions     | 6            | 8 weeks         | KPS, Barthel index              |                                             |                                        |                     |
|                      | Third study: 12 Gy/2 fractions or   | 14           | 10 weeks        | KPS, Barthel index              |                                             |                                        |                     |
|                      | 20 Gy/5 fractions                   |              |                 | of activity of daily living,    |                                             |                                        |                     |
|                      |                                     |              |                 | EORTC QLQ-30, and BCM 20        |                                             |                                        |                     |
| Kondziolka et al., 2005 | 30 Gy/12 fractions or 10 fractions | 72           |                  | KPS                             | Study-designed questionnaire                 |                                        | 2                   |
|                      | and Gamma Knife radiosurgery a     |              |                 |                                 |                                             |                                        |                     |
|                      | Gamma Knife radiosurgery a         | 32           |                  |                                 |                                             |                                        |                     |
| Li et al., 2007      | Motexafin gadolinium and 30 Gy/10   | 208          |                  | Good responders: 300±26 days    | Neurologic function classification          | Time to progression                   | 4                   |
|                      | fractions                           |              |                 | c                               |                                             |                                        |                     |
|                      |                                     |              |                 | Poor responders: 240±19 days    |                                             |                                        |                     |
|                      |                                     |              |                 |                                 |                                             |                                        |                     |
| Lock et al., 2004    | WBRT—most frequent dose fractionation: | 275         | 5.3 months      | ECOG                            |                                             |                                        | 1                   |
|                      | 20 Gy/5 fractions (6% of patients received) |              |                 |                                 |                                             |                                        |                     |
|                      | 30 Gy/10 fractions (6% received other schedules) |              |                 |                                 |                                             |                                        |                     |
| Murray et al., 1999 | 30 Gy/10 fractions                 | 182          | 4.2 months      | KPS                             |                                             |                                        | 2                   |
| Regine et al., 2004  | 37.5 Gy/15 fractions (2.5 Gy/fraction) | 55            |                  | ECOG                            | Neurologic function classification          | NCF test battery b                     | 8                   |
|                      |                                     |              |                 |                                 |                                             | MMSE, HVLT, COWA, Ruff 2 and 7 and        |                     |
|                      |                                     |              |                 |                                 |                                             | Trailmaking A and B                     |                     |
| Scott et al., 2007   | 30 Gy/10 fractions + eflaxproxir    | 57           | 9.0 months      | KPS                             | Neurologic function classification          |                                        | 4                   |
|                      | 30 Gy/10 fractions                 | 49           | 4.5 months      |                                 |                                             |                                        |                     |
|                      |                                     |              | (p=0.004)       |                                 |                                             |                                        |                     |
### TABLE VII (continued)

| Reference                  | Study arms                                | Patients (n) | Median survival | QOL assessment               | Other assessment                              | QOL instruments (n) |
|----------------------------|-------------------------------------------|--------------|-----------------|-----------------------------|-----------------------------------------------|---------------------|
| Sehlen et al., 2003 74     | CNS primary and radiotherapy              | 24           | 26.4 months    | KPS, FACT-G                 | MMSI (modified abbreviated version)           | 4                   |
|                            | Brain metastases and radiotherapy        | 33           | 28.3 months    | Current Situation in Personal Life questionnaire |                                 |                     |
|                            |                                           |              | (p=NS)          |                             |                                               |                     |
| Yaneva et al., 2006 75     | 30 Gy/10 fractions or 15 fractions        | 65           | 6.6 months     | KPS                         |                                               | 2                   |
|                            |                                           |              | 9.8 months     | EORTC QLQ-C30              |                                               |                     |

* 2–4 Brain metastases.
* Authors believed NCF and QOL correlated in this population.
* Good responders showed tumour shrinkage above the population median; poor responders showed tumour shrinkage below the population median.
* Survival length is unexpectedly long (attributable to the patient sample, which contains patients with anaplastic astrocytomas (34.4%) and brain tumours of a different histologic origin (12.5%).
* Lung cancer patients.
* Breast cancer patients.
* QOL = quality of life; ECOG = Eastern Cooperative Oncology Group Assessment; FACT-G = Functional Assessment of Cancer Therapy—General scale; FACT-BR = Functional Assessment of Cancer Therapy—Brain subscale; EORTC BCM 20 = European Organization for Research and Treatment of Cancer Brain Cancer Module; MMSI = Mini Mental Status Examination; KPS = Karnofsky performance status; ESAS = Edmonton Symptom Assessment Scale; EORTC QLQ-30 = European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire; HVLT = Hopkins Verbal Learning Test; COWA = Controlled Oral Word Association; WBRT = whole-brain radiotherapy; POMS-SF = Profile of Mood States—Short Form; MMSI = Mini Mental State Inventory; NS = nonsignificant.
### TABLE VIII  Studies focused on managing brain metastases through corticosteroids

| Reference             | Study arms                              | Patients (n) | Median survival | Overall response rate (CR+PR) | QOL assessment | Other assessment | QOL instruments (n) |
|-----------------------|-----------------------------------------|--------------|-----------------|-------------------------------|----------------|------------------|--------------------|
| Horton *et al.*, 1971  | Oral prednisone and WBRT                | 48 (total)   | 14 weeks        |                                | Performance status | Toxicity Incidence of remissions | 1                  |
|                       | Oral prednisone                         |              | 10 weeks        |                               |                |                  |                    |
| Wolfson *et al.*, 1994 | All patients: 24 mg dexamethasone every 6 hours for 48 hours | 7            | 4 months (total population) | 3 CR | 1 PR | Neurologic function classification | 2                  |
|                       | Arm 1: 4 mg every 6 hours dexamethasone with 30 Gy/10 fractions |               |                 | 8 no response |                |                  |                    |
|                       | Arm 2: 30 Gy/10 fractions               | 5            |                 |                               |                |                  |                    |

CR = complete response; PR = partial response; QOL = quality of life; WBRT = whole-brain radiotherapy; GPS = General Performance Status.

### TABLE IX  Multiple brain metastases: studies assessing the efficacy of multiple treatments

| References         | Study arms                              | Patients (n) | Median survival | QOL assessment | Tools Neurologic function or symptom control | QOL instruments (n) |
|--------------------|-----------------------------------------|--------------|-----------------|----------------|---------------------------------------------|--------------------|
| Chang *et al.*, 1992 | NSCLC patients                          |              |                 | GPS            | Neurologic function classification          | 2                  |
|                    | Surgery (4 patients received 30 Gy/15 fractions) | 9            | 9 months        |                |                                             |                    |
|                    | Chemotherapy (4 patients received 30 Gy/15 fractions) | 10           | 10 months       |                |                                             |                    |
|                    | 30 Gy/15 fractions                       | 12           | 7 months a      |                |                                             |                    |
|                    | Supportive care (2 patients received a ventriculoperitoneal shunt) | 19           | 2 months        |                |                                             |                    |
| Routh *et al.*, 1994 | WBRT                                    | 223          | 2.5 months      |                |                                             | 0                  |
|                    | Cisplatin, etoposide + WBRT             | 5            | (entire study population, WBRT + WBRI) |                |                                             |                    |
|                    | WBRT + surgery                          | 16           | from start of WBRT) |                |                                             |                    |
|                    |                                          | 32           |                 |                |                                             |                    |

a Difference between the three treatment modalities was nonsignificant.

QOL = quality of life; NSCLC = non-small-cell lung cancer; GPS = General Performance Status; WBRT = whole-brain radiotherapy; WBRI = whole-brain re-irradiation.
3.4 QOL Instruments

A total of 24 different QOL instruments, including performance scales, study-designed performance instruments, validated QOL instruments, study-designed QOL assessments, neurologic function scales, study-designed neurologic instruments, and NCF tests were used in the trials (Tables X–XIV). Six studies did not use any QOL measures.20,43,60–62,78 The most commonly used instruments were the KPS scale (n = 33) and various forms of neurologic function classification (n = 21). The number of QOL instruments used in each study varied from 0 to 8, but most of the studies used 1 (n = 26, 43%) or 2 (n = 21, 34%) instruments. Of the 23 different instruments used, 8 (35%) assessed QOL, 7 (30%) assessed NCF, 5 (22%) assessed performance status, and 3 (13%) assessed neurologic function.

Of the 8 QOL instruments used, 2 were study-designed assessments.68,74 Kondziolka et al.68 designed a 10-item survey to ask patients treated with WBRT and radiosurgery or with radiosurgery alone about their treatment perceptions, side effects (hair loss, fatigue, memory, mood or affect, intellectual concentration, employment), activity level, and overall satisfaction. This survey was used in a patient population in which 90% of the patients had a KPS status of 90 or 100. After WBRT, the side effects reported were alopecia (88%); excess fatigue (85%); problems with short-term memory (72%), long-term memory (33%), and concentration (61%); and depression (54%). Also, patients more frequently reported short-term memory problems (p < 0.0001), long-term memory problems (p = 0.03), and concentration problems (p = 0.0007) when they had undergone both WBRT and radiosurgery as compared with radiosurgery alone. More patients considered radiosurgery a good treatment for them as compared with WBRT (76% vs. 56%, p = 0.25)68.

| Table X | Frequency of instruments used in clinical trials measuring quality of life (QOL) in patients with brain metastases |
|---------|----------------------------------------------------------------------------------------------------------|
| Instrument | Frequency |
| Karnofsky performance status | 33 |
| Neurologic function classification | 21 |
| ECOG (World Health Organization) performance scores | 11 |
| General Performance Status | 5 |
| Mini Mental Status Examination | 5 |
| Study-designed performance instrument | 4 |
| Barthel index of activity of daily living | 2 |
| Controlled Oral Word Association test | 2 |
| Hopkins Verbal Learning Test | 2 |
| Spitzer quality of life index | 2 |
| Study-designed QOL assessment | 2 |
| Trailmaking A and B | 2 |
| Edmonton Symptom Assessment Scale | 1 |
| EORTC Core Quality of Life Questionnaire | 1 |
| with Brain Cancer Module | 1 |
| Functional Assessment of Cancer Therapy–General scale | 1 |
| with Brain subscale | 2 |
| Grooved Pegboard | 1 |
| Mini Mental State Inventory (modified abbreviated version) | 1 |
| Order classification | 1 |
| Profile of Mood States–Short Form | 1 |
| Ruff 2 and 7 | 1 |
| Study-designed neurologic instrument | 1 |

ECOG = Eastern Cooperative Oncology Group; EORTC = European Organization for Research and Treatment of Cancer.

| Table XI | Frequency of instruments used in assessing quality of life (QOL) in clinical trials |
|---------|------------------------------------------------------------------------------------------------|
| Instrument | Frequency |
| Spitzer quality of life index | 2 |
| Study-designed QOL assessment | 2 |
| Edmonton Symptom Assessment Scale | 1 |
| EORTC Core Quality of Life Questionnaire | 1 |
| with Brain Cancer Module | 2 |
| Functional Assessment of Cancer Therapy–General scale | 1 |
| with Brain subscale | 2 |
| Profile of Mood States–Short Form | 1 |

EORTC = European Organization for Research and Treatment of Cancer.

| Table XII | Frequency of performance score instruments used in clinical trials |
|---------|------------------------------------------------------------------------------------------------|
| Instrument | Frequency |
| Karnofsky performance status | 33 |
| ECOG (World Health Organization) performance score | 11 |
| General Performance Status | 5 |
| Study-designed performance instrument | 4 |
| Barthel index of activity of daily living | 2 |

ECOG = Eastern Cooperative Oncology Group.

| Table XIII | Frequency of neurologic function instruments used in clinical trials |
|---------|------------------------------------------------------------------------------------------------|
| Instrument | Frequency |
| Neurologic function classification | 21 |
| Order classification | 1 |
| Study-designed neurologic instrument | 1 |

| Table XIV | Frequency of neurocognitive function instruments used in clinical trials |
|---------|------------------------------------------------------------------------------------------------|
| Instrument | Frequency |
| Mini Mental Status Examination | 5 |
| Controlled Oral Word Association test | 2 |
| Hopkins Verbal Learning Test | 2 |
| Trailmaking A and B | 2 |
| Grooved Pegboard | 1 |
| Mini Mental State Inventory (modified abbreviated version) | 1 |
| Ruff 2 and 7 | 1 |
Sehlen et al. developed the Current Situation in Personal Life questionnaire because previous trials had indicated that psychological and sociodemographic variables could influence survival in cancer patients. These authors assessed patients (KPS > 70) who had undergone WBRT for primary central nervous system tumours or brain metastases; their instrument was designed to assess important sociodemographic variables and factors in the patients’ personal lives, such as marital status, number of children or people in the household, level of education, employment, family history of cancer, symptoms, relationships with family and friends, social life, hobbies, religion, and significant events. Interestingly, the results showed that “living with a spouse” had a statistically significant positive influence on survival (p = 0.033).

Addeo et al., Bezjak et al., and Sehlen et al. used the Functional Assessment of Cancer Therapy—General scale (FACT-G). This questionnaire is a validated instrument that evaluates the QOL of cancer patients in 5 domains, including physical well-being (7 items), social or family well-being (7 items), relationship with the physician (2 items), emotional well-being (5 items), and functional well-being (7 items) 79. Sehlen and her colleagues showed that the overall FACT-G score had a significant influence on survival (p = 0.003).

The FACT-G is often supplemented by site-specific questionnaires such as the FACT-Brain subscale (FACT-Brain) as used by Bezjak et al. and Addeo et al. The FACT-Brain subscale contains 19 additional items pertaining to patients with brain metastases specifically, including symptoms, self-care, cognitive ability, and ease in usual activities. Bezjak et al. found that, as compared with baseline, 8 of 23 patients showed improvement and 15 patients showed deterioration in assessed QOL using the FACT-G and FACT-Brain questionnaires 1 month after palliative radiotherapy.

The full FACT-Brain scale contains 53 questions (as compared with the subscale, with its 19 questions). Addeo et al. used the FACT-G and selected 26 items from the FACT-Brain scale to assess QOL in patients who underwent WBRT and temozolomide treatment. A significant improvement in QOL was seen with the FACT-G questionnaire (p < 0.0001). At baseline, 51% of patients reported, positively, that they were “quite a bit” or “very much” content with the quality of their life; 49% reported, negatively, that they were “not at all” or “a little bit” content with the quality of their life. Three months after treatment, 79% were content with their QOL, and 21% were not content.

Gerrard et al., Yaneva et al., and Roos et al. used the European Organization for Research and Treatment of Cancer (EORTC) Core Quality of Life Questionnaire (QLQ-C30). This general questionnaire consists of 5 domains assessing functioning (physical, role, cognitive, emotional, and social), 1 domain assessing global QOL, 3 domains assessing common symptoms (fatigue, pain, nausea or vomiting), 5 single items assessing other symptoms (dyspnea, insomnia, anorexia, constipation, and diarrhea), and 1 item assessing financial impact.

Yaneva et al. evaluated the QOL of patients with a KPS greater than 70 before and after WBRT treatment. A significant improvement was evident after radiotherapy in all domains of functioning and in all symptoms with the exception of dyspnea, diarrhea, and financial difficulties. A significant improvement in health-related QOL was also reported (p < 0.0001).

Gerrard et al. and Roos et al. used the supplementary Brain Cancer Module (BCM) in addition to the EORTC QLQ-C30. However, the BCM was designed for patients with primary brain tumour. It consists of 20 questions that assess side effects of treatment, outlook for the future, and common symptoms. Validation of this instrument in patients with brain metastases has not been reported.

When using the EORTC QLQ-C30 and BCM, Gerrard et al. experienced difficulties with data collection and found that the questionnaires were lengthy and demanding, particularly for their poor-prognosis group. From the 18 patients analyzed in their first study, high levels of fatigue and drowsiness were seen throughout the study period (baseline to 8 weeks) and only 1 patient and 2 patients improved in QOL at 2 weeks and 4 weeks respectively. Their second study, which also used the EORTC QLQ-C30 and BCM, was terminated prematurely because of difficulties with data collection. Improvement in QOL was not evident in any of the 6 patients accrued. Subsequently, in a third study, these authors simplified their QOL assessment by asking only the global health score and global QOL items of the questionnaire. Of 14 patients, 7 experienced transient improvements at some stage following WBRT.

Similarly, the randomized study of WBRT or control group post surgery or post radiosurgery by Roos et al. was also terminated prematurely because of its slow accrual. As a result of the small sample size (n = 19), the investigators did not conduct a detailed QOL analysis. They found that the differences in the global health scores and global QOL scores between the two study arms were nonsignificant at 2 months (p = 0.94) and at 5 months (p = 0.50). The investigators concluded that their study did not indicate that WBRT caused deterioration in overall health or overall QOL.

Chow et al. used the Edmonton Symptom Assessment System (ESAS) in their study of patient-rated symptoms in patients with brain metastases treated with WBRT. The ESAS is a validated instrument designed for patients receiving palliative care. It evaluates 9 symptoms, including global pain, nausea, anxiety, depression, tiredness, drowsiness, sense of well-being, appetite, and shortness of breath. Each symptom is rated on a scale from 0 to 10, where 0 represents absence of the symptom and 10 represents the worst possible symptom. The ESAS has been shown to be a quick tool to use and to predominantly reflect the physical well-being of the patient. In the study by Chow...
and colleagues, 19%, 20%, and 15% of the patients died during the first, second, and third month following WBRT. The study population had statistically significant deterioration in the mean differences between their 1-year follow-up and baseline scores for fatigue (1.0 to 1.8), drowsiness (1.2 to 1.8), and appetite (2.2 to 2.4).

Mintz et al. and Scott et al. used the Spitzer Quality of Life index (Spitzer Q-L index). This validated instrument is composed of 5 domains: general activity, daily living, health, support, and outlook. Each domain is rated from 0 to 2 and each score is accompanied by verbal descriptions. For example, for the health domain, the patient could report either feeling well or “great” most of the time (score 2), lacking in energy or being not entirely “up to par” occasionally (score 1), or feeling very ill or “lousy,” weak and washed out for most of the week (score 0).

Mintz et al. conducted a controlled trial in which patients with a single brain metastasis were randomized to either WBRT and surgery or to WBRT alone. When comparing the two study arms, the mean QOL scores were not significantly different at either of the study periods analyzed (1–3 months and 4–6 months).

Scott et al. assessed the QOL of patients randomized to WBRT with efaproxiral or to WBRT alone. At the 6-month follow-up as compared with baseline, patients in the WBRT and efaproxiral arm had higher Spitzer Q-L scores than did the patients in the WBRT arm (p = 0.019). The authors also indicated that a score of 7 or better out of 10 before treatment was a significant predictor of overall survival. Patients with a score of 7 or better experienced a 48% reduction in death rate (p = 0.0079).

Regine et al. used the Profile of Mood States—Short Form (POMS-SF), a 30-item questionnaire organized into 6 mood scales: tension–anxiety, depression–dejection, anger–hostility, vigour–activity, fatigue–inertia, and confusion–bewilderment. The individual scales are combined to achieve an indicator of overall mood. A higher mood disturbance score indicates greater mood disturbance. Although compliance rates for completion of the POMS-SF was high before treatment (95% or more), at treatment completion (84% or more), and at 1 month after treatment (70% or more), the results of the questionnaire were not reported because patient mood was not the primary objective of the study.

### 3.5 Performance Evaluation

The KPS (discussed earlier) was the tool most commonly used to assess performance status in thirty-three studies. Results from Patchell et al. are highlighted, because these authors used the KPS as a measurement of QOL when comparing patients with a single brain metastasis who had undergone either surgery and WBRT or WBRT alone. The length of time that KPS scores remained at 70 or better was used as a determinant of QOL. Patients in the surgery and WBRT arm maintained KPS scores of 70 or better for much longer than did patients who received radiation alone (38 weeks vs. 8 weeks, p < 0.005). In a prospective study, Li et al. compared the outcomes of 3 treatment arms in patients with a single brain metastasis and a KPS score of 60 or better. An increase in KPS score was seen in all 3 treatment arms: 88.9% (n = 16), 87.0% (n = 20), and 48.3% (n = 14) in patients who underwent radiosurgery in combination with WBRT, radiosurgery alone, and WBRT alone respectively. A greater improvement in KPS was seen in patients treated with radiosurgery alone or with radiosurgery in combination with WBRT.

A study by Rosenman et al. found that elective radiation could improve the QOL of patients with small-cell lung carcinoma, although it did not increase the patients’ survival. All patients initially received a standard course of WBRT. After that course of treatment, 28 patients received elective radiation, and 24 patients received radiation only when brain metastases occurred (“therapeutic radiation”). A KPS score above 60 was used by the investigators as a measure of QOL. Patients in the electively radiated arm maintained a KPS score greater than 60 for a mean time of 10 months as compared with a mean time of 6 months for patients in the therapeutically radiated arm.

The Eastern Cooperative Oncology Group (ECOG) evaluation was used in eleven of the studies to determine performance status. Unlike the KPS, which ranges from 0 to 100, the ECOG is simpler. It ranges from 0 to 4, where 0 stands for “normal activity” and 4 means “unable to get out of bed.” Roos et al. used ECOG as a part of their QOL assessment (baseline vs. first follow-up) when comparing patients randomized to WBRT or to observation after surgery or radiosurgery. No significant difference was found between the two study arms (p = 0.80).

Five of the studies used the General Performance Status (GPS), which ranges from 1, which means “normal,” to 5, which means “100% bedridden.” Also, two of the studies used the Barthel index of activity of daily living, which is a validated measure for patients with neurologic disability. Its questions focus on physical performance in 10 areas: feeding, transfers from bed to chair and back, dressing, toilet use, bathing, mobility, climbing stairs, dressing, stool control, and bladder control.

Finally, four of the studies designed their own scales to evaluate performance status. For example, Horton et al. measured performance status using a scale from 0 (“normal performance”) to 4 (“completely bedridden”). Kurtz et al. measured performance status on a scale from 0 to 100, where scores from 70 to 100 indicated ambulatory patients and scores under 70 indicated non-ambulatory patients. Harwood et al. classified the functional status of their patients by level I, II, III, and IV, where level I meant that the patient was “intellectually and physically able to work with neurological abnormalities minor or absent” and level IV meant the patient had “profound
neurologic disability." Noordijk and colleagues assessed the general well-being of the patients by designing a functionally independent survival tool. Patients were considered to be functionally independent as long as their score on the ECOG scale was 1 or lower (symptomatic, but almost completely independent) and their score on a version of a neurologic function classification was 1 or lower (patient can perform normal activities with minimal difficulties).

3.6 Evaluation of Neurologic Function and Symptoms

In 23 studies (Table XIII), a measure of the neurologic function and symptoms of the patients was reported. Various versions of a neurologic functional classification or scale was used in 20 reports. Bezjak et al. modeled an assessment tool after symptom items included in the FACT-BR and the BCM 20. This patient-rated assessment tool consisted of 16 items specific to patients with brain metastases. Symptoms were subdivided into raised intracranial pressure (3 items), effects associated with steroid use (4 items), possible subacute side effects (4 items), and effects associated with brain metastases (5 items). Robinet et al. used the order classification to record the neurologic status of the patients.

3.7 Neurocognitive Function

Li et al., Murray et al., Regine et al., Roos et al., Scott et al., and Sehlen et al. assessed NCF in their studies, five of which included the Mini Mental Status Examination (MMSE) as an instrument (Table XIV). The MMSE is a validated and easily administered tool consisting of 11 items designed to test cognitive function. It includes tests of the patient’s knowledge of orientation (1 item); memory (2 items); immediate recall (1 item); attention, concentration, and calculation (1 item); and aphasia and apraxia (4 items). Roos et al. compared the MMSE scores of patients with a single brain metastasis randomized to WBRT or to observation post surgery or post radiosurgery. Although the study was terminated prematurely because of slow accrual, no significant difference was found between the two study arms at the 12-month follow-up (p = 0.50).

The Hopkins Verbal Learning Test, which was used by Li et al., and Regine et al., is a memory test instrument and includes items for short- and long-term recall and word recognition. The Controlled Oral Word Association test used by Li et al. and Regine et al. assesses language and executive function skills where the patient’s task is to produce, in 1 minute, as many words as possible beginning with a specific letter. Additionally, trials by Li et al. and Regine et al. used the trail-making test designed to test visual motor speed and executive function.

Regine et al. included the Ruff 2 and 7 Test as a component of their NCF test battery to assess neglect, attention, and concentration. Li et al. assessed motor speed, visual–motor coordination, and single-hand dexterity with the Grooved Pegboard Test. Sehlen et al. used a modified abbreviated version of the Mini Mental State Inventory to evaluate mental capacity.

4. DISCUSSION

In recent years, QOL has become an increasingly important outcome in cancer trials. To date, fourteen trials on brain metastases that included an evaluation of the study population’s QOL have been published. Three of the trials used the FACT-G and FACT-BR instruments, three used the EORTC QLQ-C30 and BCM 20 instruments, two designed QOL instruments specifically for the trial, one used the ESAS instrument, two used the Spitzer Q-L index, and three used the KPS as a tool to evaluate QOL.

Our findings suggest that, although numerous QOL questionnaires exist, no standard questionnaire is currently used to assess QOL in patients with brain metastases. Currently, the use of these different questionnaires does not allow for a comparison of QOL across trials. A standardized tool would be beneficial for comparisons across trials and for performing meta-analyses.

Our literature review shows that certain parameters of QOL deteriorate after WBRT. Chow et al. concluded that the ESAS domains of fatigue, drowsiness, and appetite worsened after WBRT in their patients (baseline median KPS: 60; range: 20–90). In the study by Gerrard et al., 10 of the 38 patients (26%; 95% confidence interval: 13%–43%) improved in at least one of the following parameters during the study period: QOL score, Barthel index of activity of daily living, or KPS 8 weeks after WBRT. However, 14 of 15 patients had deterioration in at least one of these parameters. Using the FACT-BR questionnaire, Bezjak et al. also found deterioration in QOL from baseline to 1 month, but the difference was not statistically significant (p = 0.13). These findings have led authors to question whether patients with poor prognosis benefit from radiotherapy in terms of effect on QOL and symptom experiences.

For patients with a better prognosis, the results of Addeo et al., Yaneva et al., and Scott et al. showed that certain parameters of QOL significantly improved after WBRT. Addeo et al. used the FACT-G and 26 of the FACT-BR scale items to assess QOL in patients who underwent WBRT and temozolomide treatment. A significant improvement in QOL was seen (p < 0.0001). Three months after treatment, 79% were content with their quality of life, and 21% were discontent (compared with 51% positive respondents and 49% negative respondents at baseline).

Using a recursive partitioning analysis (RPA) based on the KPS, the Radiation Therapy Oncology Group established three prognostic classes for patients with brain metastases according to tumour, primary tumour status, presence of extracranial metastases, and age. Class included patients with a KPS of 70 or better, age below...
QUALITY OF LIFE IN BRAIN METASTASES RADIATION TRIALS

65 years, no extracranial metastases, and a controlled primary tumour; these patients had a median survival of 7.1 months. In comparison, patients with a KPS below 70 are class I with a median survival of 2.3 months. All other patients belong to class II, with a median survival of 4.2 months.

Addeo et al. 55 included a high number of patients in the RPA classes I (n = 21, 36%) and II (n = 22, 37%). That patient population differed greatly from the population included in the study by Bezjak et al. 71, where 3, 31, and 41 patients were in RPA classes I, II, and III respectively.

Yaneva et al. 75 used the EORTC QLQ-C30 in a patient population who underwent WBRT. Significant improvements in functional indicators, symptoms, and health-related QOL were found after WBRT. Those results differ from the findings of Gerrard et al. 72, who also used the EORTC QLQ-C30 questionnaire; however, the population in their study satisfied at least two of the following criteria: KPS below 70, more than 60 years of age, or a primary tumour site other than breast. In comparison, Yaneva et al. 75 selected patients who had KPS scores above 70.

Scott et al. 70 randomized patients to WBRT with efaproxiral or to WBRT alone, using the Spitzer Q-L index as a measurement of QOL. At the 6-month follow-up, patients who had received WBRT and efaproxiral had higher QOL scores than did the patients who had received WBRT alone (p = 0.019). This study population also included patients with a better prognosis (only RPA class I and II patients were included). Of the study population, 58% percent had a KPS score of 90–100, and 42% had a KPS score of 70–80.

One study found that certain parameters of QOL did not deteriorate or improve after WBRT. Roos et al. 39 randomized patients to WBRT or no additional treatment post surgery or post radiotherapy. The EORTC global health scores and global QOL scores were not significant between the study arms at 6 months (p = 0.94) and at 5 months (p = 0.50). These patients also had a fairly good prognosis: solitary brain metastasis and 14, 4, and 1 of 19 patients in RPA classes I, II, and III respectively. Although no improvement in QOL was evident, the results also did not indicate that QOL deteriorated after patients received WBRT. Poor accrual and low statistical power likely contributed to this outcome.

The present review found that few WBRT studies included a measure of QOL as a primary endpoint. A possible explanation is the difficulty in collecting data in a population of patients whose life expectancy is short. Patients with short survival and deterioration of health often contribute to high attrition rates in brain metastases QOL studies 17,72. For example, Bezjak et al. 71 found that only 19% of patients had symptomatic improvement and that 55% had either progressed in their illness or had died at 1 month. Consequently, the drop-out bias affecting research studies must be kept in mind: patients included in the results are those able to complete follow-up assessments and are thus likely have a better prognosis than are the patients lost to follow-up 11,71. Scott et al. 70 found that the Spitzer Q-L index was a better predictor of survival than the KPS was, and they suggested the use of this QOL instrument in predicting survival and assessing patient status. Sehlen and colleagues found that the overall FACT-G score had a statistically significant correlation with survival (p = 0.003). Although data collection is a challenge in this study population, the results of Sehlen et al. 73 suggest that QOL is a worthwhile endpoint to include in future brain metastases trials and that it could possibly distinguish patients with a longer expected survival.

The studies identified in this review used 55 different performance status assessment tools and 23 different neurologic function instruments. However, these instruments were primarily used to categorize the patient into prognostic groups, to describe the study population, or to act as exclusion criteria. The study by Patchell et al. 34 was an exception: the authors used the KPS to evaluate the QOL of patients before and after treatment. They determined QOL by the length of time the KPS remained at 70 or higher. Their results showed that the KPS scores of patients in the combined radiotherapy and surgery arm were maintained for a much longer period than were the scores of patients who had undergone radiotherapy alone (38 weeks vs. 8 weeks, p < 0.005) 34. Similarly, Li et al. 38 compared KPS scores from the day of treatment with scores from the first follow-up visit to determine if different treatments had an effect on the QOL of lung cancer patients with a single brain metastasis. Improvements of 88.9% (n = 16) and 87.0% (n = 20) respectively were seen in the KPS scores of patients who underwent radiosurgery in combination with WBRT and radiosurgery alone. In comparison, an improvement of 48.3% (n = 14) was seen in patients who underwent WBRT alone. A study by Rosenman et al. 63 investigated whether QOL improved with elective radiation after a standard course of WBRT in 28 patients (compared with 24 patients who received radiation therapeutically). These authors defined QOL as the length of time a patient’s KPS score remained above 60. Patients in the electively radiated arm maintained a KPS score above 60 for significantly longer than did the patients in the therapeutically radiated arm (10 months vs. 6 months).

The NCF is clearly an important concern for brain metastases patients. Although the MMSE was the most frequently used measure of NCF in the studies, it is less sensitive to mild neurocognitive impairment and may not identify subtle improvements 68,83. In addition, the MMSE has not been as thoroughly evaluated in patients with brain metastases as compared with patients with primary brain tumours 83. Hence, studies have designed NCF test batteries to thoroughly evaluate the NCF of study patients 77,83. Li et al. 76 investigated the NCF of patients who had been treated with a radiosensitizer (gadolinium) and WBRT. Patients were classified as “good” or “poor” responders depending on whether their tumour reduction at 2 months was
above or below the population median reduction of 45%. Their results showed that the “good” responders survived significantly longer than did the “poor” responders. Time to NCF deterioration was compared in the “good” and “poor” responders, and results indicated that patients with volume regression after radiation had a longer delay before NCF deterioration. The authors concluded that NCF and QOL correlated in their study population and that efforts to prevent the worsening of NCF could help maintain QOL 76.

5. CONCLUSIONS

Quality of life is an important outcome in the treatment of patients diagnosed with brain metastases. However, few clinical trials have focused on QOL as a primary outcome. Common outcomes measured are survival, response to treatment, symptomatic relief, toxicity, and duration of independent function. The present review finds that various management methods for brain metastases have been explored, and yet median survival in this patient population has not improved significantly. Thus, less-morbid treatment options that preserve or improve QOL in these patients are important.

Our literature review found that a number of QOL instruments have been used to evaluate patients with brain metastases. Additional assessment tools, including performance status tools, neurologic function assessments, and NCF tests were also used in many clinical trials to evaluate the well-being of patients. Some studies have shown that certain parameters of QOL deteriorate after WBRT in patients with poorer prognosis, but other studies have shown that QOL in patients with better prognosis improve after WBRT. Although a number of validated QOL questionnaires specific to the concerns of metastatic brain cancer patients have been developed, no standard questionnaire has currently been established for this patient population, making comparisons of QOL across trials difficult. Our findings emphasize the importance of including QOL as an endpoint in future clinical trials so as to better understand the role of QOL, especially for improving treatment in patients with brain metastases.

6. ACKNOWLEDGMENT

Our study was supported by Michael and Karyn Goldstein Cancer Research Fund.

7. REFERENCES

1. Loeffler JS, Patchell RA, Sawaya R. Treatment of metastatic cancer. In: Devita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. 5th ed. Philadelphia: Lippincott–Raven Publishers; 1997: 2523–2536.
2. Cairncross JG, Kim JH, Posner JB. Radiation therapy for brain metastases. Ann Neurol 1980;7:529–41.
3. Hoegler D. Radiotherapy for palliation of symptoms in inurable cancer. Curr Probl Cancer 1997;21:129–83.
4. Posner JB. Management of central nervous system metastasis. Semin Oncol 1977;4:81–91.
5. Lohr F, Pirzkall A, Hof H, Fleckenstein K, Debus J. Adjuvant treatment of brain metastases. Semin Surg Oncol 2001;20:50–6.
6. Murray KJ, Scott C, Greenberg HM, et al. Randomized phase III study of accelerated hyperfractionation versus standard in patients with unresected brain metastases: a report of the Radiation Therapy Oncology Group (RTOG) 9104. Int J Radiat Oncol Biol Phys 1997;39:571–4.
7. Robinet G, Thomas P, Breton JL, et al. Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe frances de pneumo-cancerologie (GFPC) protocol 95-1. Ann Oncol 2001;12:59–67.
8. Postmus PE, HaaxmaReiche H, Smit EF, et al. Treatment of brain metastases of small-cell lung cancer: comparing temiposide and teniposide with whole-brain radiotherapy—a phase III study of the European Organization for the Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 2000;18:3400–8.
9. DeAngelis LM, Currie VE, Kim JH, et al. The combined use of radiation therapy and lindomamide in the treatment of brain metastases. J Neurooncol 1989;7:241–7.
10. Borgelt B, Gelber R, Kramer S, et al. The palliation of brain metastases: Final results of the first two studies by the Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 1980;6:1–9.
11. Tsoa MN, Lloyd NS, Wong RK, et al. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2005;31:256–73.
12. World Health Organization. Preamble to the Constitution of the World Health Organization as adopted by the International Health Conference; New York, NY, U.S.A.; June 19–22, 1946. Signed on July 22, 1946 (Official Records of the World Health Organization, no. 2, p. 100). Entered into force on April 7, 1948. [Available online at: http://www.who.int/about/definition/en/print.html; cited September 10, 2008]
13. Yancik R, Edwards BK, Yates JW. Assessing the quality of life of cancer patients: practical issues in study implementation. J Psychosoc Oncol 1989;7:59–74.
14. Outcomes of cancer treatment for technology assessment and cancer treatment guidelines. J Clin Oncol 1996;14:671–9.
15. Tannock IF. Treating the patient, not just the cancer. N Engl J Med 1987;317:1534–5.
16. Bezjak A, Adam J, Panzarella T, et al. Radiotherapy for brain metastases: defining palliative response. Radiother Oncol 2001;61:71–6.
17. Chow E, Davis L, Holden L, Tsao M, Danjoux C. Prospective assessment of patient-rated symptoms following whole brain radiotherapy for brain metastases. J Pain Symptom Manage 2005;30:18–23.
18. Andrews DW, Scott CB, Sperduto PW, et al. Whole brain radiotherapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the rTOG 9508 randomised trial. Lancet 2004;363:1665–72.
19. Patchell RA, Tibbs PA, Regine WF, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998;280:1485–9.
QUALITY OF LIFE IN BRAIN METASTASES RADIATION TRIALS

20. Kondziolka D, Patel A, Lunsford LD, Kassam A, Flickinger JC. Stereotactic radiosurgery plus whole brain radiotherapy versus radiotherapy alone for patients with multiple brain metastases. *Int J Radiat Oncol Biol Phys* 1999;45:427–34.

21. Phillips TL, Scott CB, Leibel SA, Rotman M, Weigensberg JJ. Results of a randomized comparison of radiotherapy and bromodeoxyuridine with radiotherapy alone for brain metastases: Report of RTOG trial 89-05. *Int J Radiat Oncol Biol Phys* 1995;33:339–48.

22. Harwood AR, Simson WJ. Radiation therapy of cerebral metastases: a randomized prospective clinical trial. *Int J Radiat Oncol Biol Phys* 1977;2:1091–4.

23. Noordijk EM, Vecht CJ, HaaxmaReiche H, et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. *Int J Radiat Oncol Biol Phys* 1994;29:711–71.

24. Eyre HJ, Ohlsen JD, Frank J, et al. Randomized trial of radiotherapy versus radiotherapy plus methotrexate for the treatment metastatic cancer to brain. *J Neurooncol* 1984;2:325–30.

25. Rhomberg W, Eiter H, Bohrer F, Saely C, Struhal R. Combined razoxane and radiotherapy for melanoma brain metastases. A retrospective analysis. *J Neurooncol* 2005;74:295–9.

26. Taylor AE, Olver IN, Sivanthan T, Chi M, Purnell C. Observer error in grading performance status in cancer patients. *Support Care Cancer* 1999;7:332–5.

27. Murray KJ, Scott C, Zachariah B, et al. Importance of the mini-mental status examination in the treatment of patients with brain metastases: a report from the Radiation Therapy Oncology Group protocol 91-04. *Int J Radiat Oncol Biol Phys* 2000;48:59–64.

28. Haie–Meder C, Pellae–Cosset B, Laplanche A, et al. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. *Radiother Oncol* 1993;26:111–16.

29. Mintz AH, Kestle J, Rathbone MP, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. *Cancer* 1996;76:1470–6.

30. Buchanan DR, O’Mara AM, Kelaghan JW, Minasian LM. Quality-of-life assessment in the symptom management trials of the national cancer institute-supported community clinical oncology program. *J Clin Oncol* 2005;23:591–8.

31. Conill C, Verger E, Salamero M. Performance status assessment in cancer patients. *Cancer* 1990;65:1864–6.

32. Greico A, Long CJ. Investigation of the Karnofsky performance status as a measure of quality of life. *Health Psychol* 1984;3:129–42.

33. Ochs J, Mulhern R, Kun L. Quality of life assessment in cancer patients. *Am J Clin Oncol* 1988;11:415–21.

34. Patchell RA, Tibbs PA, Walsh JW, et al. A randomized trial of surgery in the treatment of single metastases to the brain. *N Engl J Med* 1990;322:494–500.

35. Epstein BE, Scott CB, Sause WT, et al. Improved survival duration in patients with unresected solitary brain metastasis using accelerated hyperfractionated radiation therapy at total doses of 54.4 gray and greater. Results of Radiation Therapy Oncology Group 85-28. *Cancer* 1993;71:1362–7.

36. Auccter RM, Lamont JP, Alexander E, et al. A multinstitutional outcome and prognostic factor analysis of radiosurgery for resectable single brain metastasis. *Int J Radiat Oncol Biol Phys* 1996;35:27–35. [See comment]

37. Jyothirmayi R, Saran FH, Jalali R, et al. Stereotactic radiotherapy for brain metastases. *Clin Oncol (R Coll Radiol)* 2001;13:228–34.

38. Li B, Yu J, Sunharalingam M, et al. Comparison of three treatment options for single brain metastasis from lung cancer. *Int J Cancer* 2000;90:37–45.

39. Roos DE, Wirth A, Burmeister BH, et al. Whole brain irradiation following surgery or radiosurgery for solitary brain metastases: mature results of a prematurely closed randomized trans-Tasman Radiation Oncology Group trial (TRG 98.05). *Radiother Oncol* 2006;80:318–22.

40. Horton J, Baxter DH, Olson KB. The management of metastases to the brain by irradiation and corticosteroids. *Am J Roentgenol Radium Ther Nucl Med* 1971;11:334–6.

41. Wolfson AH, Snodgrass SM, Schwade JG, et al. The role of steroids in the management of metastatic carcinoma to the brain. A pilot prospective trial. *Am J Clin Oncol* 1994;17:234–8.

42. Chang DB, Yang PC, Luh KT, Kuo SH, Hong RL, Lee LN. Late survival of non-small cell lung cancer patients with brain metastases. Influence of treatment. *Chest* 1992;101:1293–7.

43. Routh A, Khansur T, Hickman BT, Bass D. Management of brain metastases: past, present, and future. *South Med J* 1994;87:1218–26.

44. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1981;7:1633–8.

45. Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma: the second prospective randomized trial [Japanese]. *Nippon Igaku Hoshasen Gakkai Zasshi* 1994;54:1380–7.

46. Gelber RD, Larson B, Borgelt BR, Kramer S. Equivalence of radiation schedules for the palliative treatment of brain metastases in patients with favorable prognosis. *Cancer* 1981;48:1749–53.

47. Nieder C, Nestle U, Niewald M, Schnabl K. Accelerated radiotherapy for brain metastases. *Radiother Oncol* 1997;45:17–22.

48. Portaluri M, Bambace S, Giuliano G, et al. Fractionations in radiotherapy of brain metastases. *Tumori* 2004;90:80–5.

49. Priestman TJ, Dunn J, Brada M, Rampling R, Baker PG. Final results of the Royal College of Radiologists’ trial comparing two different radiotherapy schedules in the treatment of cerebral metastases. *Cancer* 1996;8:308–15.

50. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. *Int J Radiat Oncol Biol Phys* 1981;7:891–5.

51. Bach F, Sorensen JB, Adrian L, et al. Brain relapses in chemotherapy-treated small cell lung cancer: a retrospective review of two time-dose regimens of therapeutic brain irradiation. *Lung Cancer* 1996;15:171–81.

52. Johnson FE, Harrison BR, McKirgan LW, Raju PI, Roy TK, Virgo KS. A phase II evaluation of pentoxyfylline combined with radiation in the treatment of brain metastases. *Int J Oncol* 1998;13:801–5.

53. Kocher M, Eich HT, Semrau R, Güner SA, Müller RP. Phase II trial of simultaneous whole-brain irradiation and dose-escalating topotecan for brain metastases. *Strahlenther Onkol* 2005;181:20–5.

54. Stea B, Suh JH, Boyd AP, Cagnoni PJ, Shaw E on behalf of the
REACH Study Group. Whole-brain radiotherapy with or without efaproxir for the treatment of brain metastases: determinants of response and its prognostic value for subsequent survival. Int J Radiat Oncol Biol Phys 2006;64:1023–30.

Addeo R, Caraglia M, Faiola V, et al. Concomitant treatment of brain metastasis with whole brain radiotherapy and temozolomide (TMZ) is active and improves quality of life. BMC Cancer 2007;7:18.

Antonadou D, Coliarakis N, Paraskevaidis M, et al. Whole brain radiotherapy alone or in combination with temozolomide for brain metastases. A phase III study abstract. Int J Radiat Oncol Biol Phys 2002;54:93–4.

Guerrieri M, Wong K, Ryan G, Millward M, Quong G, Ball DL. A randomised phase III study of palliative radiation with concomitant carboplatin for brain metastases from non-small cell carcinoma of the lung. Lung Cancer 2004;46:107–11.

Hidalgo V, Dy C, Fernandez Hidalgo O, Calvo FA. Simultaneous radiotherapy and cis-platinum for the treatment of brain metastases. A pilot study. Am J Clin Oncol 1987;10:205–9.

Verger E, Gil M, Yaya R, et al. Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial. Int J Radiat Oncol Biol Phys 2005;61:185–91.

Uschinsky Y, Arita N, Hayakawa T, et al. Chemotherapy of brain metastases from lung carcinoma: a controlled randomized study. Neurosurgery 1991;28:201–5.

Hazuoka MB, Kinzie JJ. Brain metastases: results and effects of re-irradiation. Int J Radiat Oncol Biol Phys 1988;15:433–7.

Kurup P, Reddy S, Hendrickson FR. Results of re-irradiation for cerebral metastases. Cancer 1980;46:2587–9.

Rosenman J, Choi NC. Improved quality of life of patients with small-cell carcinoma of the lung by elective irradiation of the brain. Int J Radiat Oncol Biol Phys 1982;8:1041–3.

Shehata WM, Hendrickson FR, Hindo WA. Radiofrequency ablation technique and retreatment of cerebral metastases of irradiation. Cancer 1974;34:257–61.

Abdel–Wahab M, Wolfson A, Raub W, et al. The role of hyperfractionated re-irradiation in metastatic brain disease: a single institutional trial. Am J Clin Oncol 1997;20:158–60.

Jawahar A, Ampil F, Wielbaecher C, Hartman GH, Zhang JH, Nanda A. Management strategies for patients with brain metastases: has radiosurgery made a difference? South Med J 2004;97:254–8.

Pirzkall A, Debus J, Lohr F, et al. Radiosurgery alone or in combination with whole-brain radiotherapy for brain metastases. J Clin Oncol 1998;16:3563–9.

Kondziolka D, Niranjan A, Flickinger JC, et al. Radiosurgery with or without whole-brain radiotherapy for brain metastases: the patients’ perspective regarding complications. Am J Clin Oncol 2005;28:173–9.

Sneed PK, Lamborn KR, Forstner JM, et al. Radiosurgery for brain metastases: is whole brain radiotherapy necessary? Int J Radiat Oncol Biol Phys 1999;43:549–58.

Scott C, Suh J, Stea B, Nabil A, Hackman J. Improved survival, quality of life, and quality-adjusted survival in breast cancer patients treated with efaproxir (Efaproxyn) plus whole-brain radiation therapy for brain metastases. Am J Clin Oncol 2007;30:580–7.

Bezjak A, Adam J, Barton R, et al. Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 2002;38:487–96.

Gerrard GE, Prestwich RJ, Edwards A, et al. Investigating the palliative efficacy of whole-brain radiotherapy for patients with multiple-brain metastases and poor prognostic features. Clin Oncol (R Coll Radiol) 2003;15:422–8.

Lock M, Chow E, Pond GR, et al. Prognostic factors in brain metastases: can we determine patients who do not benefit from whole-brain radiotherapy? Clin Oncol (R Coll Radiol) 2004;16:332–8.

Sehlin S, Lenk M, Hollenhorst H, et al. Quality of life (QOL) as predictive mediator variable for survival in patients with intracerebral neoplasma during radiotherapy. Onkologie 2003;26:38–43.

Yaneva MP, Semerdjieva MA. Assessment of the effect of palliative radiotherapy for cancer patients with intracranial metastases using EORTC-QOL-C30 questionnaire. Folia Medica 2006;48:23–9.

Li J, Bentzen SM, Renschler M, Mehta MP. Regression after whole-brain radiation therapy for brain metastases correlates with survival and improved neurocognitive function. J Clin Oncol 2007;25:1260–6.

Regine WF, Schmitt FA, Scott CB, et al. Feasibility of neurocognitive outcome evaluations in patients with brain metastases in a multi-institutional cooperative group setting: results of Radiation Therapy Oncology Group trial BR-0018. Int J Radiat Oncol Biol Phys 2004;58:1346–52.

Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlenther Onkol 1994;170:155–61.

Weitzner MA, Meyers CA, Gelke CK, Byrne KS, Cella DF, Levin VA. The Functional Assessment of Cancer Therapy (FACT) scale. Development of a brain subscale and revalidation of the general version (FACT-G) in patients with primary brain tumors. Cancer 1995;75:1151–61.

Osoha D, Aaronson NK, Muller M, et al. The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 1996;5:139–50.

Chang VT, Hwang SS, Feuerman M. Validation of the Edmonton Symptom Assessment Scale. Cancer 2000;88:2164–71.

Spitzer WO, Dobson AJ, Hall J, et al. Measuring the quality of life of cancer patients. A concise QL-index for use by physicians. J Chron Dis 1981;34:585–97.

Herman MA, Tremont–Lukats I, Meyers CA, et al. Neurocognitive and functional assessment of patients with brain metastases. Am J Clin Oncol 2003;26:273–9.

Correspondence to: Edward Chow, Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, 2075 Bayview Avenue, Toronto, Ontario M4N 3M5.

E-mail: Edward.Chow@sunnybrook.ca

* Rapid Response Radiotherapy Program, Department of Radiation Oncology, Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Toronto, Toronto, ON.